The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Transfusion intensity in patients with JAKi-naive or JAKi-exposed MF treated with momelotinib: A longitudinal assessment
|
Momelotinib, a JAK1/2 ACVR1 inhibitor, has shown anemia-related benefits with improved transfusion independence rates in some patients with MF. A post hoc analysis examining longitudinal changes in transfusion intensity with momelotinib in patients with MF using data from phase II and III trials was published in Clinical Lymphoma Myeloma Leukemia by Claire Harrison et al. 1 The analyses included data from a phase II trial (NCT02515630; n = 41) and three phase III trials; SIMPLIFY-1 (NCT01969838; N = 432), SIMPLIFY-2 (NCT02101268; N = 156), and MOMENTUM (NCT04173494; N = 195).1 Patients received 24 weeks of momelotinib treatment in each trial.1 |
| Key learnings |
| Momelotinib provided a consistent anemia benefit for the majority of patients, with ≥77% of patients achieving improved or maintained transfusion intensity compared to baseline data across all four trials. |
|
Momelotinib reduced the mean transfusion requirement by −1.5, −0.1, −0.36, and −0.86 units per 28 days in the phase II and phase III SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM trials, respectively. 85% of patients achieved a numeric transfusion reduction in the phase II trial. |
| In SIMPLIFY-1, SIMPLIFY-2, and MOMENTUM, momelotinib showed improved or stable transfusion intensities vs ruxolitinib (87% vs 54%), BAT (77% vs 62%), and danazol (85% vs 63%). |
|
In this post hoc analysis, momelotinib was associated with anemia-related benefits in patients with MF compared to comparators. The importance of characterizing anemia-related benefits in MF therapies is highlighted by this novel time-dependent transfusion burden analysis. |
Abbreviations: ACVR1, activin A receptor type 1; BAT, best available therapy, MF, myelofibrosis; RBC, red blood cell; JAKi, Janus kinase inhibitor; TTS, Total Symptom Score.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
On average, how many patients with myelofibrosis do you see in a month?
